BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

AMAG PHARMACEUTICALS — Lobbying — Receipts Report

LD-2 disclosure · 3rd Quarter - Report

AMAG PHARMACEUTICALS

via ZIRKELBACH STRATEGIES

3rd Quarter (July 1 - Sep 30) · 2022Posted Nov 15, 2022Filing document ↗LDA record ↗

Income$45Kfee reported

Client

Name: AMAG PHARMACEUTICALS
Description: pharmaceutical company
Location: Massachusetts · United States of America

Registrant

Firm: ZIRKELBACH STRATEGIES
Description: consulting
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
Pharmaceutical issues related to womens health product access and education on the accelerated approval pathway
LobbyistsMARY KATHLEEN ZIRKELBACH
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.